ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

All Content

Jogging and bone health (Wavebreakmedia/Shutterstock.com)

Is it OK to run with knee pain? Is it a harbinger of osteoarthritis? In this slideshow, we feature some of the latest studies on knee osteoarthritis with findings that may surprise you.

(©TzidoSun/Shutterstock.com)

The Rheumatology Network Podcast: Bundled payments led to a "win-win-win-win" reality for one Texas hospital struggling to contain costs for joint replacement surgeries. In this podcast interview, two physicians discuss the complexities and benefits of bundled payments.

(Systemic Lupus Erythematosus  ©farland80/Shutterstock.com)

For systemic lupus erythematosus patients prescribed glucocorticosteroids, mortality has been found to be more frequent than in patients not prescribed glucocorticosteroids, researchers say.

Marcy B.Bolster, M.D.

Facing a growing shortage, rheumatology is looking to attract the next generation of providers.

Jonathan S. Hausmann, M.D.

Retaining international medical students, addressing student loan debt, mentoring and case-based teaching could possibly reverse the rheumatologist shortage, analysis says.

Baricitinib janus kinase inhibitor drug molecule. (Molekuul_be/Shutterstock.com)

Compared to placebo and adalimumab, the addition of once-daily oral baricitinib produced significant clinical improvements in RA patients, research shows.

Ralph Bovard, M.D.

In this article, Dr. Ralph Bovard explores osteopenia and osteoporosis. He also presents a case for creating a BMD Life Chart to track bone mineral density over a patient's lifetime.

In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.

(Psoriasis ©ChristineLangerPueschel/Shutterstock.com)

The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.

Baricitinib janus kinase (JAK1 & JAK2) inhibitor drug molecule. (Molekuul_beShut

Patient-reported outcomes are in line with clinical trial results for baricitinib, an international research team reports.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.